Narrowing the focus:Therapeutic cell surface targets for refractory triple-negative breast cancer
作者机构：Department of Cancer PhysiologyMoffitt Cancer CenterTampaFL 33612United States Department of PhysicsUniversity of South FloridaTampaFL 33612United States Division of Oncologic SciencesUniversity of South FloridaTampaFL 33612 FLUnited States Comprehensive Breast ProgramMoffitt Cancer CenterTampaFL 33612United States
出 版 物：《World Journal of Clinical Oncology》 (世界临床肿瘤学杂志（英文版）)
年 卷 期：2020年第11卷第4期
页 面：169-179页
学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
主 题：Breast cancer Triple negative Biomarker Cell surface Targeted therapy Chemorefractory
摘 要：Triple-negative breast cancer(TNBC)is defined as a type of breast cancer with lack of expression of estrogen receptor,progesterone receptor and human epidermal growth factor 2 *** comparison to other types of breast cancer,TNBC characterizes for its aggressive behavior,more prone to early recurrence and a disease with poor response to molecular target *** TNBC is identified in only 25%-30%of American breast cancer cases annually,these tumors continue to be a therapeutic challenge for clinicians for several reasons:Tumor heterogeneity,limited and toxic systemic therapy options,and often resistance to current standard therapy,characterized by progressive disease on treatment,residual tumor after cytotoxic chemotherapy,and early recurrence after complete surgical ***-surface targeted therapies have been successful for breast cancer in general,however there are currently no approved cell-surface targeted therapies specifically indicated for ***,several cell-surface targets have been identified as candidates for treatment of TNBC and associated targeted therapies are in *** purpose of this work is to review the current clinical challenges posed by TNBC,the therapeutic approaches currently in use,and provide an overview of developing cell surface targeting approaches to improve outcomes for treatment resistant TNBC.
维普期刊数据库